Table 2 CMR findings
All population (n = 130) | AMI (n = 25) | Myocarditis (n = 52) | Perimyocarditis (n = 24) | Takotsubo CMP (n = 21) | Unclear dg (n = 8) | p among groups | |
|---|---|---|---|---|---|---|---|
LV EF (%) | 57.6 ± 12.1 | 57.4 ± 13.0 | 60.1 ± 10.6 | 55.2 ± 10.8 | 50.3 ± 12.4 | 67.9 ± 10.5 | <0.001* |
EDV (ml) | 130 ± 47 | 112 ± 55 | 141 ± 41 | 149 ± 46 | 103 ± 40 | 131 ± 34 | <0.001* |
WM abnormalities (n) | 62 (47.7%) | 20 (80.0%) | 13 (25.0%) | 9 (37.5%) | 20 (95.2%) | 0 (0%) | <0.001* |
Myocardial LGE (n) | 94 (72.3%) | 21 (84.0%) | 50 (96.2%) | 21 (87.5%) | 2 (9.5%) | 0 (0%) | <0.001* |
Myocardial oedema (n) | 75 (59.1%) | 15 (65.2%) | 37 (71.2%) | 19 (79.2%) | 4 (19.0%) | 0 (0%) | <0.001* |
LV hypertrophy (n) | 27 (20.8%) | 4 (16.0%) | 7 (13.5%) | 5 (20.8%) | 7 (33.3%) | 4 (50%) | 0.118 |
Pericardial effusion and/or LGE (n) | 29 (22.3%) | 3 (12.0%) | 3 (5.8%) | 23 (95.8%) | 0 (0%) | 0 (0%) | <0.001* |